Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is universal neonatal hemoglobinopathy screening cost-effective?

R H Sprinkle1, D M Hynes, T R Konrad

  • 1Division of Policy and Ethics, Duke University-University of North Carolina Comprehensive Sickle Cell Center, Durham, NC.

Archives of Pediatrics & Adolescent Medicine
|May 1, 1994
PubMed
Summary

Universal neonatal screening for hemoglobinopathies, like sickle-cell disease, can be cost-effective. Cooperative screening arrangements can improve economic viability for states, ensuring broader access to essential health checks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On the subject of sampling . . .

American journal of health promotion : AJHP·2011
Same author

Significance of X-ray Findings in Patients with Respiratory Allergy.

Canadian family physician Medecin de famille canadien·2011
Same author

Moral suasion, installed.

Politics and the life sciences : the journal of the Association for Politics and the Life Sciences·2010
Same author

Development of a diamine biosensor.

Talanta·2008
Same author

Amperometric measuring cell for the determination of putrescine oxidase activity.

Talanta·2008
Same author

Six years and change.

Politics and the life sciences : the journal of the Association for Politics and the Life Sciences·2008

Area of Science:

  • Public Health
  • Genetics
  • Health Economics

Background:

  • Neonatal screening programs are crucial for early detection of genetic disorders.
  • Hemoglobinopathies, particularly sickle-cell disease, represent a significant public health concern.
  • Current screening practices vary across states, impacting accessibility and cost-effectiveness.

Purpose of the Study:

  • To evaluate the economic feasibility of universal neonatal screening for hemoglobinopathies.
  • To compare the cost-effectiveness of universal sickle-cell disease screening with phenylketonuria screening.
  • To explore the potential of screening cooperatives to reduce costs in high-cost states.

Main Methods:

  • Cost-effectiveness projections for nonuniversal and universal screening models.

Related Experiment Videos

  • Comparative analysis of sickle-cell disease and phenylketonuria screening costs.
  • Modeling of cooperative screening arrangements between demographically complementary states.

    • Main Results:

    • Universal screening adoption is projected to increase in some states if cost-effectiveness thresholds are met.
    • Several states currently performing screening might discontinue it independently but could benefit from cooperatives.
    • Economies of scale are achievable through cooperative screening, reducing average costs for detecting hemoglobinopathies and phenylketonuria.

    Conclusions:

    • Universal neonatal screening for hemoglobinopathies is achievable at socially acceptable costs.
    • Cooperative screening models enhance cost-effectiveness, particularly for diverse demographic states.
    • Optimizing screening strategies through collaboration can ensure wider access to vital genetic disorder detection.